PATENT CLAIM ANALYSIS

Application Number: 16239222
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["424", "488000"]

Abstract:
This disclosure relates to extended release oral dosage forms comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage forms have alcohol resistance and may also have crush resistance.

Claim (Index 13):
The dosage form of  claim 1 , wherein the high water-soluble, high dose drug is selected from quinapril, rabeprazole, dicyclomine, clindamycin, verapamil, lorsartan, trazodone, doxycycline, venlafaxine, amitriptyline, metformin, propranolol, sitagliptin, levetiracetam, levofloxacin, metoprolol, nitrofurantoin, gabapentin, promethazine, pravastatin, omeprazole, lisinopril, atomoxetine, tetracycline, oseltamivir, naproxen/sumatriptan, valacyclovir, diclofenac, bupropion, ranitidine, hydralzine and their pharmaceutically acceptable salts and solvates and mixtures thereof.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 99.0
- Lexical Diversity: 1.27778
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14296572', '13721128', '14527215', '14539231', '15210760']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8015574365205178
- 35 USC 102 Novelty (BERT): 0.5393903764808586
- Combined Prediction Score: 0.7753407305165518
- Mean Citation Score: 287.088994
- Max Citation Score: 368.59885
- Similarity Product: 274.5872726027936

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test